Amiloxate API Manufacturers

compare suppliers & get competitive offers

teaser-1024x654-1
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Amiloxate is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Amiloxate or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Amiloxate API 71617-10-2?

Description:
Here you will find a list of producers, manufacturers and distributors of Amiloxate. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Amiloxate 
Synonyms:
3-(4-Methoxyphenyl)-2-propenoic acid, 3-methylbutyl ester , Isoamyl p-methoxycinnamate , Isoamyl-p-methoxycinnamate  
Cas Number:
71617-10-2 
DrugBank number:
DB11207 
Unique Ingredient Identifier:
376KTP06K8

General Description:

Amiloxate, identified by CAS number 71617-10-2, is a notable compound with significant therapeutic applications. Amiloxate is an EMA-approved chemical UV-filter found in over-the-counter sunscreen products at concentrations up to 10%m . It is often referred to as isoamyl 4-methoxycinnamate or isoamyl p-methoxycinnamate. Amiloxate is a cinnamic acid derivative with an anti-inflammatory activity .

Indications:

This drug is primarily indicated for: Indicated as an active sunscreen agent. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Amiloxate undergoes metabolic processing primarily in: No pharmacokinetic data available. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Amiloxate are crucial for its therapeutic efficacy: According to _in vitro_ studies of amiloxate-containing tape strips on porcine ear, there was no detection of amiloxate undergoing skin penetration . The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Amiloxate is an important consideration for its dosing schedule: No pharmacokinetic data available. This determines the duration of action and helps in formulating effective dosing regimens.

Protein Binding:

Amiloxate exhibits a strong affinity for binding with plasma proteins: No pharmacokinetic data available. This property plays a key role in the drug's pharmacokinetics and distribution within the body.

Route of Elimination:

The elimination of Amiloxate from the body primarily occurs through: No pharmacokinetic data available. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Volume of Distribution:

Amiloxate is distributed throughout the body with a volume of distribution of: No pharmacokinetic data available. This metric indicates how extensively the drug permeates into body tissues.

Clearance:

The clearance rate of Amiloxate is a critical factor in determining its safe and effective dosage: No pharmacokinetic data available. It reflects the efficiency with which the drug is removed from the systemic circulation.

Pharmacodynamics:

Amiloxate exerts its therapeutic effects through: In a mouse study, amiloxate exerted a dose-dependent anti-inflammatory action and inhibited edema by about 70% even at a low dose . Due to structural similarities, amiloxate may also display antioxidant and antimicrobial properties of cinnamic acid . The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Amiloxate functions by: Amiloxate is a UV-B filter that selectively absorbs UV-B rays . It is proposed that amiloxate mediates an antioxidant action by acting as a free radical scavenger . This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Classification:

Amiloxate belongs to the class of organic compounds known as cinnamic acid esters. These are compound containing an ester derivative of cinnamic acid, classified under the direct parent group Cinnamic acid esters. This compound is a part of the Organic compounds, falling under the Phenylpropanoids and polyketides superclass, and categorized within the Cinnamic acids and derivatives class, specifically within the Cinnamic acid esters subclass.

Categories:

Amiloxate is categorized under the following therapeutic classes: Acids, Carbocyclic, Sunscreen Agents. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Experimental Properties:

Further physical and chemical characteristics of Amiloxate include:

  • Water Solubility: Insoluble
  • Melting Point:< -30
  • Boiling Point: 170

Amiloxate is a type of Anti-inflammatory Agents


Anti-inflammatory agents are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) used to treat various inflammatory conditions. These agents play a vital role in alleviating pain, reducing swelling, and controlling inflammation in the body. They are widely employed in the management of diverse medical conditions, including arthritis, autoimmune disorders, asthma, and skin conditions like dermatitis.

Anti-inflammatory APIs primarily function by inhibiting the production of specific enzymes called cyclooxygenases (COX) and lipoxygenases (LOX). These enzymes are responsible for the synthesis of pro-inflammatory molecules known as prostaglandins and leukotrienes, respectively. By suppressing the activity of COX and LOX, anti-inflammatory agents effectively curtail the production of these inflammatory mediators, thereby mitigating inflammation.

Common examples of anti-inflammatory APIs include non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, aspirin, and naproxen. These agents exhibit analgesic, antipyretic, and anti-inflammatory properties. Another group of anti-inflammatory APIs includes corticosteroids, such as prednisone and dexamethasone, which are synthetic hormones that modulate the body's immune response to control inflammation.

In conclusion, anti-inflammatory agents are a vital category of pharmaceutical APIs widely used to manage inflammation-related disorders. They target enzymes involved in the synthesis of pro-inflammatory molecules, effectively reducing pain and swelling. NSAIDs and corticosteroids are commonly prescribed anti-inflammatory APIs due to their efficacy in controlling inflammation.